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Abstract
In the event of blood vessel damage, human platelets 
are promptly recruited on the site of injury and, after 
their adhesion, activation and aggregation, prevent 
blood loss with the formation of a clot. The conse-
quence of abnormal regulation can be either hemor-
rhage or the development of thrombosis. Qualitative 
and/or quantitative defects in platelets promote bleed-
ing, whereas the residual reactivity of platelets, despite 
antiplatelet therapies, play an important role in promot-
ing arterial thrombotic complications. Platelet function 
is traditionally assessed to investigate the origin of a 
bleeding syndrome, to predict the risk of bleeding prior 
surgery or during pregnancy or to monitor the efficacy 
of antiplatelet therapy in thrombotic syndromes that, 
now, can be considered a new discipline. “Old” plate-
let function laboratory tests such as the evaluation of 
bleeding time and the platelet aggregation analysis in 
platelet-rich plasma are traditionally utilized to aid in 
the diagnosis and management of patients with platelet 
and hemostatic disorders and used as diagnostic tools 
both in bleeding and thrombotic diathesis in special-
ized laboratories. Now, new and renewed automated 
systems have been introduced to provide a simple, 
rapid assessment of platelet function including point of 
care methods. These new methodologies are also suit-
able for being used in non-specialized laboratories and 
in critical area for assessing platelet function in whole 
blood without the requirement of sample processing. 
Some of these methods are also beginning to be incor-
porated into routine clinical use and can be utilized as 
not only as first panel for the diagnosis of platelet dys-
function, but also for monitoring anti-platelet therapy 
and to potentially assess risk of both bleeding and/or 
thrombosis.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Key words: Platelets; Method; Test; Point of care test-
ing; Laboratory assessment; Bleeding; Thrombosis; 
Platelet function 
Core tip: This review discussed the scenario of available 
platelet function laboratory and point-of-care methods 
suitable in different clinical setting. As this matter has 
become of crucial importance in the bleeding man-
agement and for monitoring antiplatelet therapies, 
improved ability to assess platelet function in a timely 
and efficient manner is essential. Traditional platelet 
function methods, requiring a fair degree of expertise, 
have been limited to specialized laboratory. Many ef-
forts have been carried out for improving platelet func-
tion assays for centralized laboratory, such as different 
point-of-care testing methodologies have been devel-
oped. Moreover, different guidelines and recommenda-
tions for their method standardization are growing. 
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INTRODUCTION
Platelets are multifunctional cells that play a role in many 
pathophysiological processes including haemostasis and 
thrombosis, clot retraction, vessel constriction and repair, 
inflammation including promotion of  atherosclerosis, 
host defense and tumor growth/metastasis[1,2]. Bizzozero 
in the late 1800s first described platelets, identifying them 
as distinct cells and observing that aggregated platelets 
form thrombi into damaged parts of  vessel[3].
Notwithstanding the multiple roles of  platelets, the 
available platelet tests investigate those functions directly 
involved in haemostasis[4,5]. The fine relationships between 
platelets and the vessel wall, i.e., the primary haemostasis, 
is the first phase of  haemostatic process. At the injury of  
a vessel wall platelets are involved in sequential functional 
responses including adhesion, spreading, shape change, 
aggregation, release reaction, exposure of  a procoagulant 
surface and clot retraction. The progression of  these 
different steps conveys the activated platelets rapidly to 
form a hemostatic plug that occludes the site of  lesion 
to prevent blood loss[6]. If  one of  these functions and/or 
platelet number are defective, then hemostasis is impaired 
and an associated increased risk of  bleeding could be also 
present. On the other hand, an increase in platelet count 
or reactivity may lead to unsuitable thrombus formation. 
Upon and within atherosclerotic lesions platelets adhere, 
aggregate with the development of  arterial thrombi that 
may result in stroke and myocardial infarction, two of  the 
major causes of  morbidity and mortality in the western 
world[7]. The prevention of  arterial thrombotic complica-
tions, the antiplatelet therapy and its monitoring, can be 
beneficial, but their management should be carefully con-
ducted without increasing the risk of  bleeding[1,8-11].
To date, platelet function testing has been used to 
identify the possible causes of  bleeding[12] to monitor 
pro-haemostatic therapy in patients at high risk of  bleed-
ing and to verify normal platelet function prior and dur-
ing surgery[13,14]. Recently, different methodologies have 
progressively developed for monitoring the response to 
antiplatelet therapy and for the identification of  patients 
with residual platelet reactivity at risk of  thrombotic 
complications[15-18].
Development of platelet function testing
At the beginning of  1900s the bleeding time (BT) by 
Duke procedure[19], was the first test for evaluating the ca-
pacity of  platelets to form a plug. For long time, this test 
has been considered a useful screening test to identify 
both congenital or acquired platelet disorders[20].
The cornerstone for the diagnosis of  platelet function 
was the platelet aggregation in platelet-rich plasma (PRP) 
according to Born’s studies[21]. This method measures the 
capacity of  platelet to aggregate to each other in response 
to external aggregating agents-agonists, i.e., adenosine-
diphosphate (ADP), arachidonic acid (AA), collagen, 
epinephrine (EPI) and others[22]. Since the late 1980s new 
laboratory tests of  platelet function have become avail-
able, such as flow cytometry as well as the evaluation of  
platelet nucleotides[23]. 
Because platelet dysfunction may be due to a wide 
multiplicity of  defects, to diagnose an affected platelet 
function is difficult and there are no pivotal screening 
tests. The current laboratory assessment of  platelet de-
fects usually investigates platelet adhesion/aggregation 
and/or measurement of  granule content/release. How-
ever, these tests are labor intensive, costly, time consum-
ing and require a fair degree of  expertise and experience. 
These problems have mainly limited their extensive clinic 
use. Actually, these methodologies are available only in 
specialized clinical laboratories dedicated to the studies 
of  pathophysiological processes including haemostasis 
and thrombosis. As the evaluation of  platelet function 
has become of  crucial importance in the management of  
severe bleeding, improved ability to assess platelet func-
tion in a timely and efficient manner is essential. Dur-
ing the last two decades, different point of  care testing 
(POCT) instruments for the assessment of  platelet func-
tion at the bedside of  patients at high risk of  bleeding 
or thrombotic complications have been developed. Now, 
simple platelet function tests on whole blood (WB), that 
may be employed as POCT at bedside or within non-spe-
cialized laboratories, have been proposed[24-28]. In Table 1 
the different laboratory and point-of-care assays for the 
evaluation of  platelet function are reported; in Table 2 
advantages and disadvantages of  these methodologies are 
indicated and in Table 3 the clinical value of  the principal 
platelet tests is specified.
This report attempts to focus on the scenario of  
available platelet function POCT with the pertinent 
instrumentation more suitable for the use in different 
clinical setting of  critical area such for the diagnosis of  
inherited and acquired bleeding disorders or for monitor-
ing residual platelet reactivity of  patients on antiplatelet 
treatment.
PLATELET FUNCTION LABORATORY 
TESTING
Bleeding time
The skin Bleeding time (BT) is the oldest test for assess-
ing in vivo primary haemostasis[20]. BT assesses the capac-
ity of  platelets to form a haemostatic plug. The time, that 
the platelets employ to occlude an in vivo skin wound, is 
recorded by evaluating the ability of  platelets to stop the 
bleeding[29]. BT still remains a useful test to identify both 
congenital and acquired disorders of  primary haemosta-
sis in those laboratories that don’t perform other platelet 
function tests. The technique is easy and quick to per-
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form without any WB processing; but it can be affected 
by an inaccurate operator managing and by skin thickness 
and temperature. Notwithstanding, BT was fulfilled by 
the use of  an available device to standardize the size and 
the depth of  cut, a lack of  precision and uncertain cor-
relation with clinical patient state remain. No study has 
clearly established the ability of  BT evaluation to predict 
the risk of  bleeding in patients[30] and only a study re-
ported that BT could predict clinical bleeding in patients 
with acute myocardial infarction undergoing thrombo-
lytic therapy[31]. Moreover, this test is not used routinely 
to monitor the effect of  antiplatelet therapy[32]. 
Platelet aggregation on platelet-rich plasma 
The Light Transmission Aggregometry (LTA), method 
performed on PRP and developed in the 1960s[21,33], is 
still considered as the gold standard test for investigat-
ing platelet functions. This analysis measures in vitro the 
platelet-to-platelet aggregation in a glycoprotein(GP)Ⅱb
Ⅲa-dependent manner, the most important function of  
platelets. PRP and platelet poor plasma (PPP), obtained 
after opportune centrifugation of  citrated blood samples, 
are used to perform LTA. The addition of  an agonist to 
optically dense PRP, promotes platelet aggregation result-
ing in an increase of  brightness of  plasma sample. The 
aggregometer records the rate and extent percentage of  
increase in light transmission from 0% (maximal optical 
density of  PRP) to 100% (no optical density of  autolo-
gous PPP) by a photometer. Multi-channel easy to use ag-
gregometers are available to achieve platelet aggregation 
tests including automatic setting of  100% (PPP) and 0% 
(PRP) baselines of  light transmission, computer aid and 
storage of  results and disposable stirring bar-preloaded 
cuvettes. Different agonists can be added to PRP sample 
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Table 1  Laboratory and point-of-care assays for evaluation of platelet function
Platelet function tests Principle of method Application of the methods
Platelet adhesion studies
Bleeding time In vivo stopping of blood flow Screening test of platelet function 
on defects of primary hemostasis
Platelet Function Analyzer -  
PFA-100/InnovancePFA-200
In vitro stopping of high shear blood flow by 
platelet plug in whole blood
Assessment of bleeding risk, thrombotic risk, drug 
effects
Sensitive to severe platelet dysfunctions 
Detection of VWD
Impact Cone and Plate(let) analyzer Shear-induced platelet adhesion/aggregation 
onto surface in whole blood
Screening of congenital primary hemostasis 
abnormalities
Evaluation of platelet response to aspirin and 
clopidogrel (scarce data).
Platelet-To-Platelet Aggregation Studies
Light transmission platelet aggregation Low shear platelet-to-platelet aggregation in 
response to agonists in platelet-rich-plasma 
Screening test for bleeding behavior
Diagnostic for platelet surface
glycoprotein defects
Monitoring of the platelet response to antiplatelet 
agents
Impedance platelet aggregation  Low shear platelet-to-platelet aggregation in 
response to agonists in whole blood  
Screening test for bleeding behavior
Diagnostic for platelet surface
glycoprotein defects
Monitoring of the platelet response to antiplatelet 
agents
VerifyNow system Fibrinogen-platelet agglutination in response to 
agonist in whole blood
Monitoring of the platelet response to antiplatelet 
agents
Plateletworks Platelet counting pre- and post-activation in 
whole blood
Monitoring of the platelet response to antiplatelet 
agents
Analysis of Clot Formation
Thromboelastography/
Thromboelastometry
Monitoring of rate and quality of clot formation 
in whole blood based on viscoelastic blood 
changes
Assessment of global haemostasis 
Possible definition of different platelet and clotting 
abnormalities 
Diagnosis and treatment of bleeding after cardiac 
surgery, liver transplantation, trauma and PPH 
Platelet function tests to investigate 
platelet activation  
Flow cytometry Cell counting, cell sorting, biomarker detection 
and protein engineering laser-based detection of 
suspending fluorescent label platelets in a stream 
of fluid
Expression of platelet specific surface and/or 
cytoplasmatic  markers;  VASP  phosphorylation state1
(Monitoring of CD41/61, CD42, CD62P, etc. Activation 
markers directly dependent on thienopyridine target)
Radio- or Enzyme Linked-Immune 
Assays: Soluble markers  determination1
Ligand binding assays Measurement of Beta-thromboglobulin,  PF4, GPV, 
Soluble P-Selectin, Thromboxanes
1Not planned in this report. GP: Glycoprotein; PPH: Post-partum hemorrhage; VASP: Vasodilator-stimulated phosphoprotein; VWD: Von Willebrand Dis-
ease.
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principal pre-analytic aspects, a complete record of  
medication taken by patients should be done prior the 
blood sampling. Blood withdrawal should be atraumati-
cally performed with the use of  19 and 21 gauge needles. 
Evacuated tube systems are accepted and the anticoagu-
lant recommended is the buffered trisodium citrate at the 
concentration of  109 mmoL/L (described as 3.2%). Also 
the Anticoagulant-Citrate-Dextrose solution (formula) A 
(ACD-A), that maintains the pH at 7.2 may be used. The 
citrated blood specimens must be gently mixed, main-
tained at room temperature (RT) and softly, but rapidly, 
transferred to the laboratory. Samples should be tested 
no more than 4 h from withdrawals. Regarding some 
principal analytic aspects, the PRP should be obtained 
by centrifugation at RT at 170-200 g for 10 min, whereas 
the autologous PPP may be prepared by centrifugation 
(after removal of  PRP or using whole samples) at 1500 
g for at least 15 min at RT. The adjustment of  platelet 
in order to obtain information about many different as-
pects of  platelet function. Different parameters can be 
obtained from the evaluation of  the aggregation trace: lag 
phase, shape change, primary and secondary aggregation, 
slope, and the maximal aggregation (%) at a fixed time. 
However, despite the widespread use of  LTA test, 
it is poorly standardized and variation between labora-
tory practice has been evidenced[34,35]. Because LTA is 
recognized to be the most important and common assay 
that clinical laboratories can perform to diagnose platelet 
function disorders, its procedure is constantly substanti-
ated by an ongoing standardization process. Recently, 
specific guidelines for LTA that want to stabilize/normal-
ize  the correct procedure, have been published[36-39]. 
Concisely, these guidelines discuss the possible prob-
lematic pre-analytical, analytical and post-examination 
aspects of  LTA, in order to guide toward an accepted, 
agreed and standardized procedure. Regarding some 
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Table 2  Advantages and disadvantages of different platelet function methodologies
Platelet tests Advantages Disadvantages
Bleeding time Physiological
In vivo test
Easy, quick 
No WB processing
Operator dependent
Invasive
Poorly standardized
Dependent on different variables (skin thickness, t°C)
Light transmission platelet 
aggregation in PRP
Historical gold standard 
Flexible
Diagnostic method
Different agonists available
Sensitive for anti-plt therapy 
Pre- and analytic variables
Time-consuming
High sample volume
Sample preparation
WB Impedance Platelet 
Aggregometry 
No sample preparation
Flexible
Diagnostic method
Different agonists available
Sensitive for anti-plt therapy 
Close to POCT (Multiple system)
Limited HCT and platelet count range
Flow Cytometry Small blood volumes 
Diagnosis ex vivo of platelet activation
Evaluation of efficacy of thienopyridyne  therapy
Expensive
Specialized equipment
Experienced operator
Careful sample processing
Probable, possible artifacts 
Platelet Function Analyzer 
-PFA-100 /Innovance PFA-200
In vitro standardized BT
POCT
Easy, quick 
Sensitive to severe platelet dysfunctions
Nonflexible
Platelet count- HCT-dependent
Not sensitivity for platelet secretion defects.
VerifyNow system POCT 
WB assay
Easy, quick 
No WB processing 
Expensive
Nonflexible
Monitoring antiplatelet therapy only
Limited HCT and platelet count 
Impact Cone and Plate(let) 
analyzer
WB assay
Global platelet function
Small sample volume 
Expensive
Experienced staff
Lacking of clinical studies
Not widely available
Plateletworks POC WB system
Minimal sample preparation
Easy, rapid screening test
Indirect assay
Required platelet count method 
Not so well studied
Viscoelastic methods POCT
Global hemostasis test Anticoagulation monitoring
Predicts bleeding
Reduces blood transfusions 
Improve clinical outcome 
Measure clot properties 
Depend on: platelet function, coagulation and fibrinolysis factors 
More studies are needed
HCT: Hematocrit; plt: Platelet; POCT: Point-of-Care Testing; PRP: Platelet-rich-plasma; WB: Whole blood.
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count of  PRP is still matter of  debate. The need of  ad-
justment of  PRP with autologous PPP occurs in general 
for standardizing the platelet count between 200 and 
300 × 109 platelets/L and in particular  for lowering the 
platelet  count for matching  it with that of  a thrombocy-
topenic patient[36]. Previous in house reference intervals 
(RI) for the % maximal aggregation response specific for 
each concentration of  agonist used must be established 
on healthy adult volunteers (these RI can be applied to 
children older than neonates). LTA tracings should be 
studied and the final interpretative comment shall be or-
ganized by a laboratory physician. The principal agonists 
are commonly used  at the following  recommended 
final concentrations: ADP, 2.0-10 µmol/L; arachidonic 
acid, 0.5-1.64 mmol/L (usually 1.0 mmol/L); collagen, 1-5 
µg/mL (typically 2 µg/mL); epinephrine, 5-10 µmol/L 
(typically 5.0 µmol/L); ristocetin, 0.5-0.6 mg/mL at low 
concentration and 1.2-1.5 mg/mL at high concentration. 
To date, platelet aggregometry is still the most widely 
used method for identifying and diagnosing platelet func-
tion disorders or for monitoring antiplatelet therapies. 
Actually, this analysis is considered the first panel test 
to study hemorrhagic patient with inherited or acquired 
platelet dysfunctions[37,40-43]. When congenital/acquired 
bleeding disorders are suspected, apart from the most 
commonly agonists ADP, AA and collagen - used princi-
pally for monitoring antiplatelet therapies - other agonists 
should be also used: ristocetin, epinephrine, thrombin 
receptor activating peptide (TRAP), thromboxane A2 mi-
metic U46619, calcium ionophore A23187.
Monitoring antiplatelet therapies by using LTA allows 
to predict major adverse cardiovascular events (MACE) in 
cardiovascular patients at high risk. The rate of  residual 
platelet reactivity defined by ADP-, AA-LTA or both has 
been associated with the development of  ischemic events 
both in ACS patients and in those with stable coronary 
artery disease[44-49]. 
ADP agonist is generally used to investigate congeni-
tal/acquired bleeding disorders by LTA[22]. In the pres-
ence of  different platelet alteration, ADP induced platelet 
aggregation may result reduced (P2Y12 defects, storage 
pool deficiency of  α and δ granules, and defects of  α 
granules) or severely impaired (Glanzmann’s thrombas-
thenia)[42,50]. ADP at high concentrations (i.e., ≥ 10 µmol/
L) is used to monitor thienopyridines effect: ticlopidine, 
clopidogrel, prasugrel and ticagrelor act through the 
P2Y12 ADP receptor causing selective inhibition of  re-
sponses to ADP[44,45,51-55]. For the classification of  patients 
responsive or not to clopidogrel therapy, a collectively 
shared cut-off  value of  70% for 10 µmol/L ADP-in-
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Table 3  Major platelet function tests: Clinical value
Platelet tests Clinical value Ref.
Light transmission 
platelet aggregation 
Assessment of:
(1) idiopathic  bleeding behavior (primary hemostasis defective);
(2) residual platelet reactivity of patients on antiplatelet treatment to stratify risk of ischemic events; 
(3) detection of VWD (RIPA test);
(4) diagnostic for platelet surface glycoprotein defects. 
Moffat et al[34]
Hayward et al[41]
Gadisseur et al[43]
Breet et al[44]
Buonamici et al[45]
Paniccia et al[51,65]
Gum et al[63] 
Rechner[107]
Whole blood platelet 
aggregation
Assessment of:
(1) idiopathic  bleeding behavior (primary hemostasis defective);
(2) residual platelet reactivity of patients on antiplatelet treatment to stratify risk of ischemic events; 
(3) acquired bleeding risk: antiplatelet therapy, surgical coagulopathy;
(4) detection of VWD (RIPA test);
(5) diagnostic for HIT.
Paniccia et al[72]
Paniccia et al[73]
Sibbing et al[74]
Sibbing et al[75]
Würtz et al[77]
Bolliger et al[78]
Morel-Kopp et al[79]
Ranucci et al[81]  
Görlinger et al[84]
PFA-100
Innovance
PFA-200
Assessment of:
(1) idiopathic  bleeding behavior (primary hemostasis defective);
(2) detection of VWD; 
(3) acquired bleeding risk: anti-plt therapy, surgical coagulopathy;
(4) thrombotic risk also in relation to potential failure of anti-plt therapy; 
(5) platelet function in pregnancy, kidney or liver disease.
Hayward et al[25] 
Favaloro[94] 
Koessler et al[92] 
Marcucci et al[103] 
Reny et al[104] 
Crescente et al[105] 
Raman et al[108] 
Cammerer et al[109]
Chauleur et al[113]
VerifyNow system Assessment of:
(1) residual platelet reactivity of patients on antiplatelet treatment to stratify risk of ischemic events;
(2) low platelet reactivity of patients on antiplatelet treatment to stratify risk of bleeding events (scarce 
clinical data).
Breet et al[44]
Paniccia et al[51,65]
Tantry et al[116]
Marcucci et al[119]
Price et al[120]
Angiolillo et al[121] 
HIT: Heparin-Induced Thrombocytopenia; plt: Platelet; RIPA: Ristocetin-Induced Platelet Aggregation; VWD: Von Willebrand Disease.
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duced maximal extent aggregation was found[45,51,56,57]. AA 
is the agonist of  choice to investigate the efficacy of  the 
ASA antiplatelet therapy[58-60]. ASA is able to inhibit plate-
let aggregation by irreversible inactivation of  the COX-1 
enzyme resulting in an inhibition of  the TXA2 produc-
tion[61]. The concentrations of  1 and 1.3 mmol/L AA are 
usually used to monitor antiplatelet therapy and the cut-
off  value of  20% is used to identify patients responsive 
or not to ASA treatment[62-67]. Platelet aggregation profile 
induced by collagen (1-5 µg/mL) is characterized by a 
lag phase before aggregation arises. Collagen binds to the 
GPVI and GPⅠa/Ⅱa platelet receptors inducing granule 
release and TXA2 generation. Recently, RPR identified by 
collagen aggregation in ACS patients on ASA has been 
reported associated with cardiovascular events[67,68] and 
with the polymorphism C807T predisposing to MACE[69]. 
Collagen induced platelet aggregation can be impaired 
in different condition of  platelet function disorders, 
such as: Glanzmann’s thrombastenia, abnormalities of  
the signal-transduction pathways caused by COX-1 defi-
ciency (aspirin like defect) or defects of  platelet granules 
(α and/or δ storage pool deficiency)[42]. Epinephrine (5-10 
µmol/L) is a weak agonist that binds to the α2-adrenergic 
receptor on the surface of  platelets leading to inhibition 
of  adenylcyclase and the release of  calcium ions. Platelet 
aggregation induced by epinephrine is similar to that ob-
tained with ADP and characterized by an initial primary 
wave of  aggregation, the release of  stored ADP from the 
platelet dense bodies and second wave sustained aggrega-
tion[38]. ASA inhibits aggregation to any concentration 
of  epinephrine[67]. Impaired response to epinephrine can 
be present in some congenital platelet disorders such as 
the Wiskott-Aldrich syndrome or the Quebec platelet 
syndrome. Ristocetin (1.2-1.5 mg/mL) causes platelet 
agglutination through the Von Willebrand Factor (VWF) 
and GPIb-IX-V complex. In the presence of  Bernard-
Soulier syndrome a severely impaired platelet agglutina-
tion induced by ristocetin is present. Moreover, LTA test 
performed by using different concentrations of  ristocetin 
(0.6-1.2-1.5 mg/mL), exerts an important role to analyze 
possible VW Disease (VWD) and to differentiate the 
VWD variants[42,43].
In summary, LTA test is considered the first diagnostic 
step in the evaluation of  platelet disorders. Since these 
platelet alterations are complex, in order to perform a 
diagnostic hypothesis, LTA results should be supported 
by further and more specific tests. Lumiaggregometry 
method for the identification of  impaired platelet secre-
tion (i.e., the measurement of  the platelet content of  ad-
enine nucleotide and serotonin), flow cytometry analysis 
or western blotting test for the identification of  expres-
sion of  specific platelet component and the evaluation of  
deficiency of  α and δ granules by electron microscopy 
can specifically confirm the LTA results and should be 
performed as second diagnostic step[42].
Platelet aggregation on WB 
Platelet aggregation on WB is achieved by impedance 
platelet aggregometry, based on the principle that acti-
vated platelets expose their surface receptors which allow 
them to bind to artificial surfaces[70,71]. This test measures 
the change in electrical resistance or impedance between 
two electrodes set at a fixed distance within WB sample. 
The platelet adhesion to electrodes and the response to 
classical agonists get other platelets aggregate to those 
stacked to the electrodes, increasing the impedance. The 
extent of  the increase in impedance is normally recorded 
in Ohm. The use of  WB allow to assess platelet function 
under more physiological conditions taking into account 
that also the contributions of  other blood elements that 
may affect platelet function. In addition, another impor-
tant aspect is that WB aggregometry takes place on sur-
faces. Platelet aggregation on WB has many advantages 
as well as the use of  small sample volume, the immediate 
analysis without no sample manipulation, loss of  time or 
possible failure of  subpopulation of  platelets. 
Recently, a new multiple electrode aggregometry 
(MEA) by using a five channel computerized WB ag-
gregometer (Multiple Platelet Function Analyzer - Dyna-
byte - Roche Diagnostics, Germany) equipped by dispos-
able cuvettes ready to use with two independent sensor 
units and an automated pipetting has become available. 
The increase of  impedance is detected for each sensor 
unit separately and calculated automatically as area under 
curve (AUC). By using this device with these advantages, 
MEA has acquired the high valence for being consid-
ered a POCT. Because MEA may use different agonists 
(similarly to LTA), it is suitable for diagnosis of  bleeding 
and also for monitoring antiplatelet therapy[72-77]. Indeed, 
MEA has been used to investigate the presence of  VWD 
in patient with severe aortic stenosis[78] and on the other 
hand the high thrombotic risk due to heparin induced 
thrombocytopenia (HIT)[79].
In particular, MEA, beyond the identification of  
cardiovascular patients at risk of  MACE[72-75], is able to 
discriminate those patients that have a too much high 
inhibition of  platelet function and at risk of  bleeding[80]. 
In the same manner, Ranucci et al[81] reported that the use 
of  MEA before cardiac surgery allowed to identify those 
patient at risk of  bleeding. Different reports elucidated 
that MEA might be able to identify preoperatively those 
patients at risk of  blood loss after cardiac surgery[82,83] 
and it is de facto entered as rapid and useful tool for the 
management of  postoperative severe bleeding[84]. More 
recently, Malek et al[85] reported that low extent of  TRAP-
induced platelet aggregation by using this method was 
a factor independently associated with intramyocardial 
hemorrhage of  patients with myocardial infarction.
Flow cytometry platelet analysis
Platelet analysis by using flow cytometry (FC) may offer 
information on the functional status in vivo of  platelets[23]. 
This technique allows the evaluation of  the physical and 
antigenic properties of  platelets, i.e., surface expression 
of  receptors, bound ligands, secretion, presence of  plate-
let aggregates and leukocyte-platelet aggregates. FC is 
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able to measure cell size and granularity of  a large popu-
lation of  cells, not only the platelets and to quantify the 
fluorescence emitted by fluorochrome-labeled antibodies 
and ligands bound to the cells evaluated.
FC can be a useful tool for the diagnosis of  inherited 
or acquired platelet dysfunctions (i.e., Bernard- Soulier 
Syndrome or HIT, respectively). In addition, FC is able to 
recognize the pathological activation state of  platelets (i.e., 
in the setting of  acute coronary syndromes or cardiopul-
monary bypass); the efficacy of  antiplatelet drugs[86] and, 
finally, the state of  stored platelet for the evaluation of  
efficacy of  platelet transfusion[87,88].
A panel of  antibodies may be used to study in detail 
the membrane glycoprotein receptors of  platelets. To 
count binding, antibodies may be directly conjugated 
with different fluorochromes such as fluorescein isothio-
cyanate (FITC) or phycoerythrin (PE). But, also a specie-
specific secondary antibody coupled to a fluorochrome 
can be used to recognize a primary antibody linked to 
surface antigens[23]. For FC both PRP and WB can be 
used. Prior fixation of  platelets with paraformaldehyde 
stabilizes surface antigens and consents transport of  re-
agent components. In the WB, the use of  a double label-
ing binding allows the identification of  platelets or mixed 
cell aggregates[89,90]. The results of  FC are represented in 
the form of  histograms with mean fluorescence intensity 
(MFI) plotted against cell number.
PLATELET FUNCTION POINT-OF-CARE 
TESTING
The Platelet Function Analyser - PFA-100/ Innovance 
PFA-200
This POC method PFA-100/Innovance PFA-200 (Sie-
mens, Munich, Germany) assesses platelet function in 
WB and has been considered the standardization of  
BT[24,25,91]. The PFA-100 and the updated system In-
novance PFA-200[92] by using apposite cartridges simu-
lates primary haemostasis under shear stress conditions. 
Citrated WB is drew at high shear stress rate through a 
defined microscopic aperture (147 µm) into a collagen-
coated membrane (C) filled with either epinephrine (EPI), 
CEPI cartridge, or ADP, CADP cartridge. In response to 
shear stress and agonists platelets undergo adhesion and 
aggregation upon the membrane forming a platelet clot 
which occludes the aperture. The time taken to occlude 
the hole is the closure time (CT), a measure of  overall 
platelet-related haemostasis and this interval will be pro-
longed depending on the platelet activity. The use of  two 
different cartridges with distinct agonists allows to dis-
tinguish the platelet function alterations due to intrinsic 
defects (principally by using CADP cartridge) or to anti-
platelet therapy with ASA (CEPI cartridge)[93-97], whereas 
the new Innovance cartridge is affected by thienopyridine 
therapy[98]. In comparison to BT test, this method is 
revealed more sensitive[27,46] especially for diagnosis of  
VWD and platelet function defects[25].
The PFA-100 is sensitive to many variables that in-
fluence platelet function as well as low platelet count 
and haematocrit. Thus, to exclude thrombocytopenia or 
anemia, a WB count should always be performed prior 
test. In addition, it has been demonstrated that different 
determinants such as high levels of  VWF, fibrinogen or 
erythrocytes tend to shorten CEPI CT[99,100]. Moreover, 
the PFA CT by CEPI cartridge could reveal high residual 
platelet reactivity despite aspirin therapy, and conse-
quently predict the risk of  ischemic events[101-103]. In ACS 
patients on ASA treatment, a high concordance between 
LTA and PFA-100 CEPI test results and a significant 
negative predictive value for the PFA system have been 
reported[65]. In addition, PFA CEPI shortened CT was 
demonstrated to be significant and independent predic-
tor of  MACEs in patients with AMI undergoing primary 
PCI[103-105].
Assessment of  platelet dysfunction with PFA-100 in 
different clinical setting or in patients undergoing different 
kinds of  elective surgeries, may provide useful information 
for postoperative blood transfusion management[106,107]. 
Especially in cardiac surgery PFA methodology showed a 
high predictive value of  platelet function for management 
of  intra- and postoperative blood loss[108-111]. In patients 
with biventricular assist device implantation on treatment 
with clopidogrel, the strict monitoring of  impaired plate-
let function with this method (by using CADP cartridge) 
allowed them to go under successful transplantation with 
no major blood loss[112]. Prolonged CTs by CADP assay 
were found be independent risk factors for post-partum 
hemorrhage (PPH) severity[113] and prolonged CTs by 
CADP cartridge have been consistently described to 
be correlated in women with menorrhagia[114]. The pre-
surgical correction of  the prolonged PFA-100 CT with 
DDAVP treatment, allowed to maintain the number of  
postoperative blood transfusions not significantly differ-
ent from that of  patients with normal presurgical PFA 
CT[106].
It has been suggested that PFA system could be used 
as a screening tool that could be integrated into a panel 
of  existing tests[38,42]. In particular, it is reported that this 
test presents a high negative predictive value[63,96]: so, in 
the presence of  normal CT in a suspected platelet defect, 
further detailed analysis, e.g., platelet aggregation, might 
be eliminated from the investigation[5]. 
VerifyNow system
The VerifyNow system (ITC, Edison, NJ, United States) 
is a POC turbidimetric-based optical detection device that 
measures platelet aggregation in a system cartridge con-
taining fibrinogen-coated beads and specific agonist[115]. 
The instrument measures changes in light transmission 
and thus records the rate of  aggregation in WB. This 
methodology originally was developed for monitoring 
antiplatelet therapy with to GPⅡb/Ⅲa antagonists. Now, 
the system provides other 2 different assays each sensi-
tive to targeted drugs: Aspirin Assay with AA as agonist 
(sensitive to ASA) and P2Y12 Assay with ADP as agonist 
and PGE1 as suppressor of  intracellular free calcium lev-
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els to reduce the non-specific contribution of  the ADP-
binding to P2Y1 receptors (sensitive to thienopyridines). 
The VerifyNow system allows a rapid assessment of  the 
platelet function also without the requirement of  a spe-
cialized laboratory. Since the VerifyNow is a cartridge-
based WB assay, it is not necessary to perform tests with 
any blood manipulation and instrument handling. Actu-
ally, this methodology is so waived that it is largely used 
to monitor antiplatelet therapies[116]. 
For Aspirin Assay, results are expressed as Aspirin 
Reaction Units (ARU) and for the identification of  re-
sponsiveness to ASA treatment a specific cut-off  value 
of  550 ARU is recommended by manufacturers[117]. In 
stroke patients on low dose of  ASA[96] and in coronary 
artery disease patients on dual antiplatelet therapy[65,46,118] 
a moderate agreement between VerifyNow system and 
LTA results was observed. For the VerifyNow P2Y12 as-
say results are expressed as P2Y12 Reaction Units (PRU). 
Different laboratory and clinical studies relative to patient 
on different thienopyridines have tried to choose a cut-
off  value for discriminating patients not responsive to 
drug[44,51,119-122]. 
The potential role of  this system for prediction of  
postoperative bleeding in surgical practice remains placed 
for the evaluation of  the extent of  inhibition of  platelet 
function in response to antiplatelet medication[123]. Ac-
tually, by using this system antiplatelet therapy for out-
patients or patients immediately after surgery could be 
tailored to the individual depending on the results. 
Plateletworks
Plateletworks system is a POC assay based on platelet 
aggregation on WB. This system consists of  the Platelet-
works aggregation kits and the Ichor blood counter 
(Helena Laboratories, Beaumont, TX, United States). 
The Plateletworks procedure compares the platelet count 
measured in the control sample (EDTA tube) with those 
obtained after aggregation in citrate blood with either 
collagen, ADP or AA (citrate tube plus agonist). Plate-
let aggregation is measured as the decrease of  platelet 
count. Results are available in minutes and without any 
manipulation of  blood sample[124]. This method has 
showed a relationship with LTA, VerifyNow system and 
Thromboelastography[125,126] and may be used to monitor 
antiplatelet therapy[127]. Plateletworks gives information 
about both platelet count and function within an acute 
care situation. However, it is still under consideration and 
has not reported to predict clinical outcomes.
IMPACT Cone And Plate(Let) Analyzer
IMPACT (Image Analysis Monitoring Platelet Adhesion 
Cone and Plate Technology) Cone and Plate(let) Analyzer 
(CPA) (DiaMed, Cressier, Switzerland) is a new POC 
completely automated system that evaluates platelet func-
tion simulating in vitro primary haemostasis[4,27,28,128]. Ci-
trated WB is exposed to shear stress by the spinning of  a 
cone in a standardized polystyrene plate. After automated 
staining, the percentage of  the well surface covered by 
platelet aggregates -representing platelet adhesion - and 
the average size of  the aggregates (per µm2) - represent-
ing platelet aggregation - are measured by image analysis 
software. 
This system is highly dependent on plasma VWF, fi-
brinogen binding the platelet glycoproteins GPIb and GP
Ⅱb/Ⅲa to the plastic surface. Therefore, this instrument 
methodology should be a reliable device for the diagnosis 
of  platelet defects. Moreover, the addition of  the ago-
nists AA and ADP in the system allows to monitor dual 
antiplatelet therapy[128-130]. This system still needs an ex-
perienced use and additional studies must be conducted 
for assessing its possible role for monitoring inherited or 
acquired platelet dysfunctions.
Viscoelastic methods
These methods are global tests for the assessment of  
haemostatic process, based on the measurements of  
changes in viscoelastic forces in WB. These analyses are 
able to assess the extent of  platelet count  and function, 
clotting and fibrinolytic activation[131,132]. To date, three 
principal systems are available: Thromboelastography, 
performed on “old” renewed devices (TEG, Haemo-
scope, Niles, IL, United States), Thromboelastometry, 
formerly called Rotational Thromboelastography, per-
formed on a new device (ROTEM , TEM Int., Munich, 
Germany) and Sonoclot analysis performed on a new 
device (Sonoclot Signature, Sienco, Boulder, CO, United 
States). All these systems providing a graphic representa-
tion of  clot formation and lysis, are now used as a bed-
side monitor in different clinical setting such as cardiac 
surgery, liver transplantation and trauma center[133,134]. For 
TEG and ROTEM, in a rotating system consisting of  
a pin suspended by a torsion wire in a cup the WB clot 
entraps the pin promoting a motion that increases as the 
clot strengthens and decreases when the clot lyses. In So-
noclot device in the cup the pin is moved up and down at 
ultrasonic rate. 
Different studies[135-142] reported these systems to be 
predictive of  risk of  increased postoperative bleeding. 
Other reports have stated the use of  different parameters 
provided by these tests are predictors of  both postopera-
tive bleeding and blood product use[143-145]. 
Thrombelastograph Platelet Mapping System has 
been developed to monitor antiplatelet therapy[146-149]. 
A weak clot is formed by the addition of  reptilase and 
factor XIII, by adding AA or ADP the clot strength is 
increased allowing this assay to be sensitive to dual anti-
platelet therapy. 
However, further large prospective studies should be 
performed in order to define the possible role of  these 
devices in monitoring antiplatelet therapy.
FUTURE PERSPECTIVES
As reported in this review, several in vitro tests for the 
assessment of  platelet (dys)function in order to screen 
different idiopathic or acquired pathological conditions 
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-hemorrhagic and/or prothrombotic status - have been 
developed. Now, platelet testing is mostly used thanks 
also to the recent and constant standardization effort. 
These available tests allow to study global platelet func-
tion  including  the different steps of  platelet activation. 
For example, the POC platelet tests simultaneously evalu-
ate in vitro platelet adhesion and aggregation; platelet ag-
gregometry in PRP and in WB (by using the new Multi-
plate system) is a comprehensive examination of  platelet 
secretion and aggregation phenomena, also considering 
the role of  other blood cells (platelet aggregation in WB); 
viscoelastic methods analyze the global hemostasis with 
the regard of  clot retraction (Tables 2 and 3).
To date, platelet function tests are available to address 
the different phases of  platelet activation. Platelet assays, 
evaluating platelet adhesion under static or flow condi-
tions and platelet spreading have been developed[107,150]. 
Platelet adhesion tests in static condition, using a large 
number of  different surfaces - glass beads, cultured vas-
cular cells, purified matrix proteins or complete subendo-
thelial extracellular matrix from cultured endothelial cells 
- that goes to the detriment of  univocal results and stan-
dardized procedure,  might be achieved[151]. Under flow 
conditions, platelets adhesion is affected by rheological 
conditions such as shear rate, presence of  red blood cells, 
red blood cell deformability, and viscosity of  the medi-
um. In this multitude of  conditions, platelet adhesion can 
be evaluated by using microfluidic devices for example 
biochip containing several different adhesion mole-
cules[152,153]. Platelet spreading tests, using fluorescence mi-
croscopy or scanning electron microscopy are frequently 
employed[154]. Platelet secretion may be evaluated measur-
ing the concentration of  several compound released - 
nucleotides (ATP, ADP), serotonin (5-HT), Platelet Fac-
tor 4 (PF4), beta-thromboglobulin , thrombospondin-1) 
by using different methodologies such as: ELISA, HPLC, 
fluorescence microscopy or  flow cytometry[42,155,156]. The 
assessment of  these distinct steps - platelet adhesion, 
secretion and interactions with circulating cells - might 
be helpful to better define pathological conditions related 
to different platelet dysfunction. However, most of  these 
assays, prevalently aimed for research studies show differ-
ent clinical impact and methodological challenges. Main 
limitations of  the application of  these assays in clinical 
practice are the scarcity of  clinical and laboratory data, 
often divergent each other, and the lack of  clear indica-
tions or guidelines for a correct use of  such tests. In the 
future, specific, standardized, more rapid and easy tests - 
whose clinical value has been well defined - for the study 
of  single steps of  platelet function or for the definition 
of  clinical value of  new platelet biomarkers by using new 
tests showing high sensitivity  and specificity,  are desir-
able for routinely laboratory analysis. 
New potential biomarkers of platelet activation
Recent studies have shown that the interaction of  activat-
ed platelets with CD34+ cells might potentially contrib-
ute in the differentiation of  CD34+ cells to endothelial 
progenitor cells (EPCs)[157] and mature endothelial cells 
(EC)[158]. The identification of  cellular mediators, tissue 
specific chemokines, factors and molecular determinants 
involved in this interactions could be useful to identify 
new strategies for the vascular repair and tissue regenera-
tion in ischemic organs[159,160]. 
In this contest, the chemokine CXCL12 (stromal cell-
derived factor-1α, SDF-1α), principally produced by 
platelet and stored in α granules, but also released from 
endothelial cells, is directly involved[161]. The principal 
role of  CXCL12 is related to the  platelet activation ac-
companied with P-selectin expression and release of  dif-
ferent platelet chemokines[162,163]. In the site of  vascular 
injury, CXCL12 stimulates the differentiation of  CD34+ 
cells into EPCs and ECs, so exerting an important role 
in neointima formation[157,162]. Actually, the measure-
ment  of  CXCL12 and/or the rapid identification of  
platelet-CD34+ cell complexes in the future might be 
used,  on hand, as assessment of  a predictive biomarker 
of  ischemic events in combination with other vascular 
parameters and, other hand,  to early detect CD34+ cells 
as biomarkers for cardiovascular diseases or for tissue re-
newal and/or repair.
CONCLUSION
New guidelines for platelet function testing have been 
written in the 2011[38] and, recently, new procedures for 
improving the ongoing standardization of  LTA have 
been reported in the 2013[39]. From the late 1980’s to 
nowadays, the study effort, in the field of  application of  
platelet function methods as diagnostic tool for evaluat-
ing bleeding disorders and monitoring the efficacy of  
antiplatelet therapies, is at this time again in progress. 
However, the increasing number of  new POC methods 
for the assessment of  platelet function is making possible 
the introduction of  these tests into the routine laboratory 
and opening the door for the their application in differ-
ent clinical settings such as inherited bleeding disorders, 
cardiovascular intensive care, trauma coagulopathy, liver 
transplantation and obstetric care for the prediction of  
bleeding. 
To date, the improvement of  reliable, advanced and 
innovative, but simple to use WB methodologies, that 
simulate primary hemostasis, is allowing to screen rapidly 
patients and to guide the clinicians for an appropriate 
diagnosis of  bleeding risk or for tailoring correctly the 
antiplatelet therapy. Surely, the general consensus is that 
the in vivo BT should be replaced. On the other hand, the 
use of  platelet aggregometry in PRP of  WB at the light 
of  new instruments should be implemented into routine 
laboratories. Similarly, some POC platelet function tests 
could also be, actually, used as instruments for evaluating 
bleeding risk, thrombotic risk and monitoring antiplatelet 
therapy not only at the bedside, but also in centralized 
or in satellite laboratories. Conversely, platelet function 
testing is become increasingly used in critical area outside 
of  the specialized laboratory. Although the presence of  
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these new methodologies represents an important im-
provement, a validation procedure, the study of  reliability 
and quality control testing of  these point of  care tests is 
becoming an increasingly important issue[38].
In conclusion, old and new platelet function tests are 
now available. Many tests are beginning to prove to be 
useful supplements to the existing set of  platelet function 
tests, but large prospective well designed clinical trials are 
necessary for defining the true applications of  these tests. 
In the future, the developments in platelet genome and 
proteome may lead advances in the field of  platelet func-
tion testing which may have a significant impact upon the 
diagnosis and management of  patient affected by hemor-
rhagic or thrombotic defects.
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